Yeast; Media Therefor Patents (Class 435/254.2)
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140342404Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.Type: ApplicationFiled: April 10, 2013Publication date: November 20, 2014Applicant: GENENTECH, INC.Inventor: Leonard G. PRESTA
-
Publication number: 20140342431Abstract: Compositions and methods relating to variant alpha-amylases are described.Type: ApplicationFiled: December 18, 2012Publication date: November 20, 2014Applicant: Danisco US INC.Inventors: Luis Gustavo Cascao-Pereira, Marc Kolkman
-
Publication number: 20140345004Abstract: The disclosure relates to the field of glyco-engineering, more specifically, to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells are glyco-engineered yeast cells in which, additionally, at least one exogenous enzyme needed for complex glycosylation is present, e.g., allowing easier separation of differentially glycosylated glycoproteins.Type: ApplicationFiled: July 2, 2014Publication date: November 20, 2014Inventors: Nico L.M. CALLEWAERT, Karen DE POURCQ, Steven GUYSENS, Leander MEURIS
-
Publication number: 20140343267Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.Type: ApplicationFiled: April 24, 2014Publication date: November 20, 2014Applicant: ABBVIE INC.Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
-
Publication number: 20140342414Abstract: The present disclosure relates to biocatalytic methods or processes for the synthesis of acrylic acid and its derivatives, or other carboxylic acid compounds of the formula R—CO2H, wherein R is a carbon chain of 5 carbons or fewer, such as methacrylic acid or 3-hydroxypropionic acid. More specifically, the disclosure relates to methods of using an acyl-CoA hydrolase (such as a thioesterase) as a biocatalyst for the hydrolysis (and removal of the CoA moiety) of a substrate acyl-CoA compound to produce the corresponding carboxylic acid compound, such as acrylic acid. In some embodiments, the disclosure provides non-naturally occurring microorganisms that have been transformed with a heterologous acyl-CoA hydrolase, such as a thioesterase, that is capable of hydrolyzing an acyl-CoA produced in a pathway of the microorganism and produce the corresponding carboxylic acid compound, thereby allowing methods for the direct fermentative production of the compound.Type: ApplicationFiled: September 21, 2012Publication date: November 20, 2014Applicant: Codexis, Inc.Inventors: Fernando Valle, Nicholas John Agard, Christopher Noriega
-
Publication number: 20140342451Abstract: The invention provides a method of incorporating nonstandard amino acids into a protein by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs.Type: ApplicationFiled: August 8, 2014Publication date: November 20, 2014Inventors: Inchan Kwon, David Tirrell
-
Publication number: 20140342424Abstract: Provided are: a novel yeast having an ability to efficiently produce ethanol from glucose and xylose in a short time in the coexistence of the glucose and the xylose; and a method for producing ethanol using the novel yeast. A yeast, which was designated as Candida intermedia 4-6-4T2 and was deposited as FERM BP-11509.Type: ApplicationFiled: October 24, 2012Publication date: November 20, 2014Applicant: COSMO OIL CO., LTD.Inventor: Hiroshi Nagasaki
-
Publication number: 20140341910Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: November 26, 2013Publication date: November 20, 2014Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Patent number: 8889391Abstract: The present disclosure provides novel beta-alanine/alpha ketoglutarate aminotransferase nucleic acid and protein sequences having increased biological activity. Also provided are cells containing such enzymes, as well as methods of their use, for example to produce malonyl semialdehyde and downstream products thereof, such as 3-hydroxypropionic acid and derivatives thereof.Type: GrantFiled: September 12, 2011Date of Patent: November 18, 2014Assignee: Cargill, IncorporatedInventors: Holly Jean Jessen, Hans H. Liao, Steven John Gort, Olga V. Selifonova
-
Patent number: 8889381Abstract: Provided herein are diterpene synthases (diTPS) and methods for producing diterpenoids. Also provided herein are nucleic acid sequences encoding diTPS, diTPS amino acid sequences, diTPS proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.Type: GrantFiled: November 21, 2012Date of Patent: November 18, 2014Assignee: University of British ColumbiaInventors: Joerg Bohlmann, Philipp Zerbe
-
Patent number: 8889397Abstract: A selectively inducible, single-stranded DNA (ssDNA) expression library, a method for constructing a ssDNA expression library, a method for screening ssDNA using the expression library, and a method for identifying ssDNA molecules that alter expression of bacterial and fungal gene(s) related to cell growth and toxin production and secretion. The screening library is used to, among other things, identify ODNs effective in stopping cell growth, killing bacteria or fungi, or preventing bacteria and/or fungi from synthesizing and secreting their toxins, and/or to discover ODNs effective in eukaryotic (e.g., mammalian) cells for targeted alteration of gene function. The library is also useful for identifying ssDNAs or ODNs that are used as therapeutic agents for, for instance, providing a method for treatment of bacterial infections such as sepsis.Type: GrantFiled: June 3, 2004Date of Patent: November 18, 2014Assignee: Star Biologics, Inc.Inventors: Yin Chen, Xin Xing Tan
-
Publication number: 20140335579Abstract: The present invention relates to polynucleotides from Cochliobolus heterostrophus C5, Cyanothece sp. CCY0110, Mycocentrospora acerin and Hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides according to the invention, and to the polypeptides encoded by the polynucleotides. The invention furthermore relates to antibodies against the polypeptides according to the invention. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions and to their use as drugs, cosmetics, foodstuffs, feedstuffs, preferably fish food, or food supplements.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Inventors: Toralf Senger, Jörg Bauer, Johnathan A. Napier
-
Publication number: 20140336119Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.Type: ApplicationFiled: September 7, 2012Publication date: November 13, 2014Applicant: INSTITUT PASTEURInventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
-
Publication number: 20140335572Abstract: Provided are isolated polypeptides having catalase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 19, 2012Publication date: November 13, 2014Inventors: Ye Liu, Junxin Duan, Yu Zhang, Lan Tang
-
Publication number: 20140335014Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 8, 2014Publication date: November 13, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
-
Publication number: 20140336363Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 12, 2012Publication date: November 13, 2014Applicant: Hoffmann-La Roche Inc.Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
-
Publication number: 20140335091Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.Type: ApplicationFiled: May 2, 2014Publication date: November 13, 2014Applicant: RINAT NEUROSCIENCE CORP.Inventors: Alison Jane FORGIE, Javier Fernando CHAPARRO RIGGERS, Edward Roland LAVALLIE, Chia-Yang LIN, Lidia MOSYAK, Andrea ROSSI, Thomas John VAN BLARCOM
-
Publication number: 20140336236Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.Type: ApplicationFiled: April 21, 2014Publication date: November 13, 2014Applicant: FOUNDATION MEDICINE, INC.Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
-
Publication number: 20140335101Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: February 27, 2014Publication date: November 13, 2014Applicant: Ablynx N.V.Inventor: Els Anna Alice Beirnaert
-
Patent number: 8883483Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: GrantFiled: June 9, 2011Date of Patent: November 11, 2014Assignee: GlycoFi, Inc.Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-kwon Choi, Juergen Nett, Piotr Bobrowicz, Stephen Hamilton, Robert Davidson
-
Patent number: 8883445Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: GrantFiled: July 13, 2007Date of Patent: November 11, 2014Assignees: Research Corporation Technologies, Inc., Universiteit Gent, Vib, VZWInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Patent number: 8883482Abstract: The present invention relates to methods for increasing homologous recombination of a nucleic acid sequence introduced into a host cell, comprising: (a) introducing into a population of filamentous fungal host cells a first nucleic acid sequence encoding a recombination protein and a second nucleic acid sequence comprising one or more regions which are homologous with the genome of the filamentous fungal host cell, wherein (i) the recombination protein promotes the recombination of the one or more regions with the corresponding homologous region in the host's genome to incorporate the second nucleic acid sequence by homologous recombination, and (ii) the number of host cells comprising the incorporated second nucleic acid sequence in the population is increased at least 20% compared to the same population without the first nucleic acid sequence; (b) and isolating from the population a filamentous fungal cell comprising the incorporated second nucleic acid sequence.Type: GrantFiled: June 28, 2013Date of Patent: November 11, 2014Assignee: Novozymes, Inc.Inventors: Paul Harris, Howard Brody
-
Publication number: 20140328831Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Inventors: William D. Carlson, Peter C. Keck
-
Publication number: 20140328797Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.Type: ApplicationFiled: April 28, 2014Publication date: November 6, 2014Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
-
Publication number: 20140328791Abstract: Conjugates of an IL-2 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.Type: ApplicationFiled: November 11, 2011Publication date: November 6, 2014Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Harold Zappe, Yujun Wang, Jicai Huang
-
Publication number: 20140328875Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
-
Publication number: 20140328829Abstract: Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.Type: ApplicationFiled: July 5, 2012Publication date: November 6, 2014Inventors: Dawei Li, Zhenghua Wu, Hao Guo, Qi Zhu, Dhahiri S. Mashausi
-
Publication number: 20140328751Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: April 9, 2014Publication date: November 6, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20140329291Abstract: Disclosed are methods and compositions related to ONC-T18, D4-desaturases, D5 elongases, their isolation, characterization, production, identification, and use for fatty acid production, as well as organisms containing these compositions and organisms expressing them.Type: ApplicationFiled: May 6, 2014Publication date: November 6, 2014Applicant: DSM Nutritional Products AGInventors: Adam M. Burja, Gabrielle S. Chafe, Helia Radianingtyas
-
Publication number: 20140329276Abstract: Methods for increasing the yield and N-glycosylation site occupancy of paucimannose or complex N-glycans of recombinant glycoproteins produced in a recombinant host cell lacking dolichyl-P-Man:Man5GlcNAc2-PP-dolichyl alpha-1,3 mannosyltransferase (Alg3p) activity are disclosed. In particular, recombinant host cells are provided that comprise a disruption of the expression of an OS-9 family gene in the host cell. These recombinant host cells may then be used for producing recombinant glycoproteins. In further embodiments, the recombinant host cells further overexpress at least one heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex.Type: ApplicationFiled: October 23, 2012Publication date: November 6, 2014Applicant: MERCK SHARP & DOHME CORP.Inventors: Byung-Kwon Choi, Stephen R. Hamilton, Natarajan Sethuraman
-
Publication number: 20140329916Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as adipate, 6-aminocaproate, hexamethylenediamine or caprolactam. Also provided herein are methods for using such an organism to produce adipate, 6-aminocaproate, hexamethylenediamine or caprolactam.Type: ApplicationFiled: December 16, 2013Publication date: November 6, 2014Applicant: Genomatica, Inc.Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
-
Publication number: 20140331364Abstract: Provided are isolated polypeptides having beta-glucosidase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 19, 2012Publication date: November 6, 2014Inventors: Ye Liu, Junxin Duan, Yu Zhang, Lan Tang
-
Publication number: 20140329745Abstract: The present invention provides a human insulin analogue, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analogue and an application of the insulin analogue as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.Type: ApplicationFiled: November 22, 2012Publication date: November 6, 2014Inventors: Piaoyang Sun, Lianshan Zhang, Jiajian Liu, Jijun Yuan, Chunqian Fang, Changan Sun, Hengli Yuan, Yali Wang
-
Publication number: 20140329287Abstract: Described herein, inter alia, are compositions, oleagnious organisms, and methods useful for producing lipids, lipid precursors, and/or oleochemicals.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Applicant: Board of Regents, The University of Texas SystemInventors: John Blazeck, Andrew Hill, Leqian Liu, Hal Alper
-
Publication number: 20140328849Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.Type: ApplicationFiled: March 14, 2014Publication date: November 6, 2014Applicant: GENENTECH, INC.Inventors: Karin REIF, Isidro HOTZEL, Jo-Anne S. HONGO, Tao HUANG, Yonglei SHANG, Meredith HAZEN
-
Publication number: 20140329250Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.Type: ApplicationFiled: May 30, 2014Publication date: November 6, 2014Inventors: Satoshi INOUYE, Yuiko SAHARA
-
Patent number: 8877205Abstract: Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.Type: GrantFiled: February 9, 2012Date of Patent: November 4, 2014Assignee: GlobeImmune, Inc.Inventors: David Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
-
Patent number: 8877915Abstract: Disclosed are: transcription regulatory factors capable of regulating the transcription or expression of genes for mannanases or cellulases, as mentioned below; and others. Specifically disclosed is a protein selected from the following proteins (a), (b) and (c): (a) a protein comprising the amino acid sequence depicted in SEQ ID NO:2; (b) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues (e.g., 1 to 5 amino acid residues) in the amino acid sequence depicted in SEQ ID NO:2 and which is capable of regulating the transcription of genes for mannanases or cellulases; and (c) a protein which comprises an amino acid sequence having a 70% or higher sequence identity to the amino acid sequence depicted in SEQ ID NO:2 and which is capable of regulating the transcription of genes for mannanases or cellulases, or a partial fragment of the protein. Also specifically disclosed are a gene encoding the protein, and others.Type: GrantFiled: March 2, 2010Date of Patent: November 4, 2014Assignees: National Institute of Advanced Industrial Science and Technology, Noda Institute for Scientific ResearchInventors: Masahiro Ogawa, Yasuji Koyama, Masayuki Machida
-
Patent number: 8877474Abstract: The present invention provides various GH61 protein variants comprising various amino acid substitutions. The GH61 protein variants have an improved ability to synergize with cellulase enzymes, thereby increasing the yield of fermentable sugars obtained by saccharification of biomass. In some embodiments, sugars obtained from saccharification are fermented to produce numerous end-products, including but not limited to alcohol.Type: GrantFiled: August 22, 2012Date of Patent: November 4, 2014Assignee: Codexis, Inc.Inventors: Jie Yang, Xiyun Zhang, Jungjoo Yoon, Kripa Rao, John H. Grate, David Elgart, Dipnath Baidyaroy
-
Publication number: 20140322221Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.Type: ApplicationFiled: March 28, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Kathy L. MILLER, Leonard G. PRESTA
-
Publication number: 20140323348Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
-
Publication number: 20140322812Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: April 24, 2014Publication date: October 30, 2014Applicant: Intrexon CorporationInventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
-
Publication number: 20140325692Abstract: The present invention provides methods for light-dependent gene regulation using a light-responsive DNA-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive DNA-binding protein or DNA-binding sites recognizing the light-responsive DNA-binding protein. Kits using the present light-dependent gene regulation system are further provided by the present invention.Type: ApplicationFiled: November 16, 2012Publication date: October 30, 2014Inventors: Kevin H. Gardner, Laura B. Motta-Mena, Brian D. Zotowski
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140322753Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: June 30, 2014Publication date: October 30, 2014Inventors: Paul Harris, Elena Vlasenko, Marcus Sakari Kauppinnen, Elizabeth Zaretsky, Sarah Teter, Kimberly Brown
-
Publication number: 20140322779Abstract: Provided herein are non-naturally occurring eukaryotic organisms that can be engineered to produce and increase the availability of cytosolic acetyl-CoA. Also provided herein are non-naturally occurring eukaryotic organisms having a 1,3-butanediol (1,3-BDO) pathway, and methods of using such organisms to produce 1,3-BDO.Type: ApplicationFiled: November 12, 2012Publication date: October 30, 2014Inventors: Anthony P. Burgard, Mark J. Burk, Robin E. Osterhout, Priti Pharkya, Jingyi Li
-
Publication number: 20140322796Abstract: The invention relates to recombinant expression of variant forms of C1 CBH1a and homologs thereof, having improved thermostability, low-pH tolerance, specific activity and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.Type: ApplicationFiled: May 9, 2014Publication date: October 30, 2014Applicant: Codexis, Inc.Inventors: Vesna Mitchell, Grzegorz Wojciechowski, Oscar Alvizo
-
Publication number: 20140322773Abstract: Provided is a method for producing lactic acid which does not require neutralization and crude purification associated therewith both of which give a high load to the environment. A method for producing lactic acid, which comprises subjecting glucose to lactic acid fermentation by using a fission yeast having a lactic acid fermentation ability and recovering lactic acid produced thereby, characterized in that a fermentation liquor created from an aqueous glucose solution by lactic acid fermentation is replaced with an aqueous glucose solution having a potassium ion concentration of at least 400 ppm to continue the lactic acid fermentation, and the replacement of the fermentation liquor with the potassium ion-containing aqueous glucose solution is performed at least once.Type: ApplicationFiled: August 20, 2013Publication date: October 30, 2014Applicant: Asahi Glass Company, LimitedInventors: Futoshi HARA, Hideki Tohda
-
Publication number: 20140322768Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum